All enrolled individuals who received at the very least just one dose of zosuquidar or placebo throughout induction were monitored with the incidence of adverse functions (439 sufferers, 219 on zosuquidar and 210 on placebo). The commonest adverse functions had been associated with the duration of prolonged and significant myelosuppression https://andyz211lxh4.estate-blog.com/profile